Cargando…

Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia (AML)

Acute myeloid leukemia (AML) is a life-threatening stem cell disease characterized by uncontrolled proliferation and accumulation of myeloblasts. Using an advanced RNAi screen-approach in an AML mouse model we have recently identified the epigenetic ‘reader’ BRD4 as a promising target in AML. In the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Herrmann, Harald, Blatt, Katharina, Shi, Junwei, Gleixner, Karoline V., Cerny-Reiterer, Sabine, Müllauer, Leonhard, Vakoc, Christopher R., Sperr, Wolfgang R., Horny, Hans-Peter, Bradner, James E., Zuber, Johannes, Valent, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2012
Materias:	Research Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681497/ https://www.ncbi.nlm.nih.gov/pubmed/23249862

Ejemplares similares

Immunotherapy-Based Targeting and Elimination of Leukemic Stem Cells in AML and CML
por: Valent, Peter, et al.
Publicado: (2019)

Identification of bromodomain-containing protein 4 (BRD4) as a novel marker and epigenetic target in mast cell leukemia
por: Wedeh, Ghaith, et al.
Publicado: (2015)

FLAG-induced remission in a patient with acute mast cell leukemia (MCL) exhibiting t(7;10)(q22;q26) and KIT D816H()
por: Valent, Peter, et al.
Publicado: (2013)

BRD4: A BET(ter) target for the treatment of AML?
por: Valent, Peter, et al.
Publicado: (2014)

Evaluation of efficacy of alemtuzumab in 5 patients with aplastic anemia and/or myelodysplastic neoplasm
por: Füreder, Wolfgang, et al.
Publicado: (2016)

Identification of heat shock protein 32 (Hsp32) as a novel target in acute lymphoblastic leukemia
por: Cerny-Reiterer, Sabine, et al.
Publicado: (2014)

TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML
por: Valent, Peter, et al.
Publicado: (2017)

Maintenance therapy with histamine plus IL-2 induces a striking expansion of two CD56(bright) NK cell subpopulations in patients with acute myeloid leukemia and supports their activation
por: Cuapio, Angélica, et al.
Publicado: (2016)

Evaluation of in vitro effects of various targeted drugs on plasma cells and putative neoplastic stem cells in patients with multiple myeloma
por: Blatt, Katharina, et al.
Publicado: (2016)

Clonal Hematopoiesis with Oncogenic Potential (CHOP): Separation from CHIP and Roads to AML
por: Valent, Peter, et al.
Publicado: (2019)

Long-term treatment with imatinib results in profound mast cell deficiency in Ph+ chronic myeloid leukemia
por: Cerny-Reiterer, Sabine, et al.
Publicado: (2014)

Multidisciplinary Challenges in Mastocytosis and How to Address with Personalized Medicine Approaches
por: Valent, Peter, et al.
Publicado: (2019)

Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?
por: Schulenburg, Axel, et al.
Publicado: (2015)

Cell‐based and antibody‐mediated immunotherapies directed against leukemic stem cells in acute myeloid leukemia: Perspectives and open issues
por: Valent, Peter, et al.
Publicado: (2020)

Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts
por: Valent, Peter, et al.
Publicado: (2023)

The pan-BCL-2-blocker obatoclax (GX15-070) and the PI3-kinase/mTOR-inhibitor BEZ235 produce cooperative growth-inhibitory effects in ALL cells
por: Stefanzl, Gabriele, et al.
Publicado: (2017)

Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells
por: Fiskus, Warren, et al.
Publicado: (2021)

Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma
por: Brien, Gerard L, et al.
Publicado: (2018)

BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph(+) chronic myeloid leukemia
por: Peter, Barbara, et al.
Publicado: (2022)

Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells
por: Peter, Barbara, et al.
Publicado: (2017)

C/EBPα: critical at the origin of leukemic transformation
por: Roe, Jae-Seok, et al.
Publicado: (2014)

BRD4-mediated repression of p53 is a target for combination therapy in AML
por: Latif, Anne-Louise, et al.
Publicado: (2021)

Low-dose salinomycin induces anti-leukemic responses in AML and MLL
por: Roulston, Gary D.R., et al.
Publicado: (2016)

Phenotyping and Target Expression Profiling of CD34(+)/CD38(−) and CD34(+)/CD38(+) Stem- and Progenitor cells in Acute Lymphoblastic Leukemia
por: Blatt, Katharina, et al.
Publicado: (2018)

The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis
por: Schneeweiss, Mathias, et al.
Publicado: (2018)

Brd4 regulates the expression of essential autophagy genes and Keap1 in AML cells
por: Huang, Min, et al.
Publicado: (2018)

Molecular quantification of tissue disease burden is a new biomarker and independent predictor of survival in mastocytosis
por: Greiner, Georg, et al.
Publicado: (2020)

Sensitivity and engineered resistance of myeloid leukemia cells to BRD9 inhibition
por: Hohmann, Anja F., et al.
Publicado: (2016)

Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML
por: Haubner, S., et al.
Publicado: (2018)

β-catenin and γ-catenin are dispensable for T lymphocytes and AML leukemic stem cells
por: Zhao, Xin, et al.
Publicado: (2020)

The underestimated role of basophils in Ph(+) chronic myeloid leukaemia
por: Valent, Peter, et al.
Publicado: (2018)

BTK inhibition is a potent approach to block IgE‐mediated histamine release in human basophils
por: Smiljkovic, D., et al.
Publicado: (2017)

Standards and Impact of Hematopathology in Myelodysplastic Syndromes (MDS)
por: Valent, Peter, et al.
Publicado: (2010)

Genome-wide co-occupancy of AML1-ETO and N-CoR defines the t(8;21) AML signature in leukemic cells
por: Trombly, Daniel J, et al.
Publicado: (2015)

CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1(T315I)+ clones in TKI-resistant CML
por: Schneeweiss-Gleixner, Mathias, et al.
Publicado: (2019)

Interleukin-9 (IL-9) and NPM-ALK each generate mast cell hyperplasia as single ‘hit’ and cooperate in producing a mastocytosis-like disease in mice
por: Merz, Hartmut, et al.
Publicado: (2010)

PB2476: TARGETING OF BRD4 TO COUNTERACT CYTOKINE-INDUCED EXPRESSION OF PD-L1 AND PD-L2 ON VASCULAR, OSTEOBLASTIC AND STROMAL NICHE CELLS
por: Filik, Yüksel, et al.
Publicado: (2023)

Therapeutic Vulnerabilities in FLT3-Mutant AML Unmasked by Palbociclib
por: Uras, Iris Z., et al.
Publicado: (2018)

CDK4/CDK6 Inhibitors Synergize with Midostaurin, Avapritinib, and Nintedanib in Inducing Growth Inhibition in KIT D816V(+) Neoplastic Mast Cells
por: Schneeweiss-Gleixner, Mathias, et al.
Publicado: (2022)

Exploiting Mitochondrial Dysfunction for Effective Elimination of Imatinib-Resistant Leukemic Cells
por: Kluza, Jérome, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_417fs8rt8jdislkorjb009jhq3